Altimmune (NASDAQ:ALT) Trading Up 6.4%

Altimmune, Inc. (NASDAQ:ALT)’s stock price rose 6.4% on Wednesday . The company traded as high as $7.53 and last traded at $7.34. Approximately 2,322,961 shares changed hands during trading, a decline of 51% from the average daily volume of 4,719,188 shares. The stock had previously closed at $6.90.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Piper Sandler restated an “overweight” rating and issued a $25.00 price target on shares of Altimmune in a research report on Friday, June 21st. JMP Securities decreased their target price on Altimmune from $25.00 to $24.00 and set a “market outperform” rating for the company in a research note on Friday, May 10th. Guggenheim lowered Altimmune from a “buy” rating to a “neutral” rating in a report on Monday, April 29th. HC Wainwright reissued a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Tuesday, May 14th. Finally, B. Riley restated a “buy” rating and set a $20.00 price objective on shares of Altimmune in a research note on Tuesday, June 25th. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $18.80.

Altimmune Trading Up 2.9 %

The stock has a fifty day moving average price of $7.06 and a two-hundred day moving average price of $8.74.

Altimmune (NASDAQ:ALT) last posted its earnings results on Thursday, May 9th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.02. Altimmune had a negative return on equity of 46.96% and a negative net margin of 22,645.37%. The firm had revenue of $0.01 million for the quarter. During the same quarter in the prior year, the business earned ($0.40) earnings per share. On average, sell-side analysts forecast that Altimmune, Inc. will post -1.34 EPS for the current year.

Institutional Trading of Altimmune

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Timelo Investment Management Inc. raised its holdings in Altimmune by 2,597.0% during the fourth quarter. Timelo Investment Management Inc. now owns 809,095 shares of the company’s stock worth $9,102,000 after purchasing an additional 779,095 shares in the last quarter. Knoll Capital Management LLC raised its stake in shares of Altimmune by 183.6% in the 1st quarter. Knoll Capital Management LLC now owns 567,219 shares of the company’s stock worth $5,774,000 after buying an additional 367,219 shares in the last quarter. Farallon Capital Management LLC lifted its holdings in shares of Altimmune by 1,282.4% in the first quarter. Farallon Capital Management LLC now owns 470,000 shares of the company’s stock valued at $4,785,000 after buying an additional 436,000 shares during the period. Lighthouse Investment Partners LLC bought a new position in Altimmune during the fourth quarter valued at about $4,493,000. Finally, Gerber LLC grew its holdings in Altimmune by 10.2% during the first quarter. Gerber LLC now owns 281,778 shares of the company’s stock worth $2,868,000 after acquiring an additional 26,000 shares during the period. 78.05% of the stock is currently owned by institutional investors.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.